Journalist

&
""
Latest by
Galaxy AI Class Surpasses 200,000 Graduates, Introduces Galaxy XR Experience
Galaxy AI Class Surpasses 200,000 Graduates, Introduces Galaxy XR Experience

Samsung Electronics announced on November 16 that it has introduced a new Galaxy Extended Reality (XR) experience to its mobile artificial intelligence (AI) education program, the Galaxy AI Class. This initiative aims to enhance AI learning experiences in classrooms using headset-type mobile devices.According to Samsung, the XR experience will be offered to middle school students in grades 7 and 8 who choose the 'Travel' theme during their second-period elective classes. Classes that opt for the XR experience will receive a 15-minute demonstration from a professional instructor, followed by a 10-minute hands-on session with student representatives from each group. Participants will wear the devices to indirectly experience key features of multimodal AI.Specifically, students will engage in activities such as object searches using 'Circle to Search,' AI conversations with 'Gemini Live,' immersive 3D map experiences, and viewing three-dimensional reconstructed images.The Galaxy AI Class, launched in January 2025, is a school visit-based educational program. Professional and assistant instructors visit upper-grade elementary and middle school students to teach a first period on 'AI Fundamentals' and a second period on elective practice. The program has been refined through a content advisory committee composed of internal and external experts, incorporating feedback from current teachers and adapting to school environments.In just one year and ten months since its launch, the program has surpassed 200,000 graduates. Notably, during the recruitment for the second semester of this year, 173 schools and approximately 22,000 students applied within the first day. Samsung plans to provide AI education to an additional 70,000 students in the second semester, aiming for a total of over 250,000 students in two years.Im Seong-taek, Vice President of Samsung Electronics Korea, emphasized, "Through Galaxy XR, students will have a more diverse experience with AI and expand opportunities to connect with their areas of interest."* This article has been translated by AI.

Mokpo City Council Chair Park Soo-kyung Criticizes Health Administration Failures
Mokpo City Council Chair Park Soo-kyung Criticizes Health Administration Failures

Mokpo City Council Chair Park Soo-kyung criticized the city's health administration during an administrative audit, highlighting the suspension of basic health services and delays in replacing outdated medical equipment. She called for practical measures to protect citizens' health rights.According to the Mokpo City Council, Chair Park (Yongdang 1, Yongdang 2, Yeondong, Samhak-dong) demanded responsible responses from the administration regarding recurring issues during the 409th Second Regular Session's administrative audit held on November 16, 2026.Park specifically pointed out the complete suspension of basic health services, such as blood sugar testing at the Hadang Health Center, due to the lack of public health doctors. She emphasized that residents should not be left inconvenienced solely due to a shortage of medical personnel.She urged the health center to establish a system for the guidance and supervision of doctors and to consider realistic alternatives, such as rotating medical staff, to promptly resume basic health services.Regarding the issue of outdated medical equipment, Park noted that it has been raised for three consecutive years without being included in the implementation plan. She stated that failing to address these recurring issues could undermine the effectiveness of the administrative audit and called for a specific equipment replacement plan and timeline.The working conditions and safety management of disinfection workers were also scrutinized. Park stressed the need for effective safety management measures, including regular health check-ups and the provision of appropriate protective gear, to safeguard the health and safety of workers on the front lines.She also called for strengthened oversight of mental health facilities. Park urged thorough inspections of the hygiene management practices and the protection of residents' rights at the 11 mental health facilities in the area, as well as follow-up checks on identified issues.Additionally, she raised concerns about the financial burden associated with expanding support for dementia treatment management costs. Park indicated that with the anticipated increase in eligible recipients due to the removal of income restrictions, a long-term financial plan should be established to prepare for the expected rise in municipal expenses.She pointed out that for the policy of expanding support to translate into stable welfare services, sustainable financial measures must be in place.Park Soo-kyung stated, "We must correct the practice of omitting repeatedly raised issues from the planning stage and ensure that the administration takes responsibility to implement practical improvement measures to protect citizens' health rights and ensure the safety of frontline workers."During the administrative audit, Park outlined key improvement tasks, including normalizing basic health services at the Hadang Health Center, establishing a plan for replacing outdated medical equipment, ensuring safety management for disinfection workers, strengthening oversight of mental health facilities, and securing funding for dementia treatment management costs.* This article has been translated by AI.

Robert Pattinson Cast as Next James Bond, First 007 of Amazon Era
Robert Pattinson Cast as Next James Bond, First 007 of Amazon Era

British actor Robert Pattinson has been confirmed as the next James Bond. This will be the 26th 007 film, marking the first production since Amazon acquired creative control of the Bond series.On November 16, Amazon MGM Studios announced Pattinson's casting via social media and a press release. The 40-year-old actor will become the seventh actor to portray Bond, following Sean Connery, George Lazenby, Roger Moore, Timothy Dalton, Pierce Brosnan, and Daniel Craig. Denis Villeneuve, known for the 'Dune' series, will direct, while Steven Knight, creator of 'Peaky Blinders,' will write the screenplay. The title and release date have not yet been disclosed.Pattinson expressed his excitement in a statement, saying, "James Bond is one of the most legendary characters in cinema, and being cast as 007 is a lifelong honor. This role is a dream come true." Villeneuve praised Pattinson, stating, "He possesses the eternal soul of 007 and brings a completely new energy to the role." This film will be the first to emerge after longtime series producers Barbara Broccoli and Michael G. Wilson transferred creative control to Amazon. The BBC reports that the film is expected to be released in 2028, marking a seven-year gap since 'No Time to Die,' the longest hiatus in the series' history. Pattinson also stars in Villeneuve's 'Dune: Part 3,' which is set to be released next month.* This article has been translated by AI.

SK Securities Lowers CJs Target Price Amid Slowing Growth from Olive Young Store Closures
SK Securities Lowers CJ's Target Price Amid Slowing Growth from Olive Young Store Closures

SK Securities announced on November 17 that it has lowered its target price for CJ to 150,000 won due to slowing revenue growth resulting from the closure of low-performing stores by its subsidiary Olive Young. The investment recommendation remains a 'buy.'Choi Kwan-soo, a researcher at SK Securities, stated in a report that despite balanced growth in both online and offline channels, the closure of low-performing stores has led to a slight slowdown in year-on-year revenue growth for Olive Young.Choi projected Olive Young's revenue for this year to reach 6.9 trillion won. Currently, the company operates two offline stores and an online mall in the United States, with plans to open five additional stores by the first half of next year.He noted that while the third quarter did not reflect U.S. performance, results from the U.S. market are expected to be included starting next year, leading to a recovery in growth rates and profitability.Additionally, Choi pointed out that CJ's stock has fallen 35% since the beginning of the year, which is excessive compared to declines in major subsidiaries such as CJ CheilJedang (-14%), CJ CGV (-14%), and CJ Freshway (-22%). He anticipates that while Olive Young's performance has slowed due to its U.S. expansion this year, a recovery is expected starting next year.Furthermore, he mentioned that the likelihood of Olive Young's listing has decreased in the short term due to revised exchange guidelines on dual listings, suggesting that the value of Olive Young is currently underestimated. He predicts that CJ's stock will rebound flexibly once performance from its U.S. expansion is confirmed next year.* This article has been translated by AI.

Aribios AR1001 Achieves Primary Goal in Phase 3 Trial, No Difference in Overall Patient Group
Aribio's AR1001 Achieves Primary Goal in Phase 3 Trial, No Difference in Overall Patient Group

Aribio's oral Alzheimer's treatment candidate, AR1001 (ingredient name mirodenafil), has achieved its primary evaluation goal in a global Phase 3 clinical trial. The drug demonstrated effectiveness in a group that did not take existing dementia medications. This finding is significant as it confirms the potential of an oral drug in a market primarily dominated by injectable treatments.On November 16, during the Clinical Trials on Alzheimer's Disease (CTAD 2026) conference in Boston, Aribio presented the 52-week results of the global Phase 3 trial (POLARIS-AD) for AR1001. The trial involved 1,535 early Alzheimer's patients from 13 countries, who took either 30 mg of AR1001 or a placebo once daily for 52 weeks.The trial was designed to evaluate two groups: the overall patient population and a subgroup of 604 patients who were not taking existing dementia medications. Achieving statistical significance in either group would fulfill the primary goal. In the subgroup, patients receiving AR1001 experienced a 0.44-point smaller decline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) score compared to the placebo group, indicating a 31% slowdown in disease progression.However, the overall patient group showed only a 0.11-point difference, failing to achieve statistical significance. Secondary endpoints, including cognitive function, also did not show meaningful differences between the two groups. The incidence of serious adverse events was similar, with 10.0% in the treatment group and 9.8% in the placebo group.These results are directly linked to commercialization efforts. In May, Aribio signed a $4.74 billion global exclusive option agreement for AR1001 with China's Puxing Pharmaceutical, covering major markets including the U.S., Europe, and Japan, excluding South Korea, the Middle East, and Latin America.However, the inability to demonstrate efficacy in the overall patient group remains a challenge. Industry experts believe Aribio will pursue regulatory approval based on the results from the subgroup. The key question will be whether regulatory authorities will grant approval based solely on these findings.* This article has been translated by AI.

2026 Hampyeong Winter Light Festival to Begin December 18
2026 Hampyeong Winter Light Festival to Begin December 18

The winter nights in Hampyeong, South Jeolla Province, will be illuminated by a spectacular light festival. Hampyeong County announced on November 17 that the '2026 Hampyeong Winter Light Festival' will take place from December 18 to 31 at Hampyeong Expo Park and the town center. Now in its third year, this festival will showcase a variety of nighttime displays, performances, and interactive programs under the theme 'Hampyeong Nights, A Festival of Lights!' This year, the festival will expand beyond Hampyeong Expo Park to include the town center, aiming to increase visitor stay time and boost the local economy. The Expo Park will feature themed nighttime displays such as 'Mythical Light Garden' and 'Light Garden.' A large Christmas tree and various light sculptures will adorn the winter nights, while newly introduced three-dimensional media art will provide visitors with unique visual experiences. The town center will also be transformed with light displays. Key areas will feature a 'Light Street' adorned with light gateways and photo zones, along with a special stage and street parades offering diverse performances. Visitors will be able to enjoy nighttime scenery at the Expo Park before moving to the town center for performances, food, and local shopping, highlighting the festival's expanded space. Family-friendly interactive programs will also be enhanced. Activities such as wish lantern releases, classic car exhibitions, and winter-themed experiences will encourage participation, transforming the festival into an engaging winter celebration rather than just a visual display. To stimulate the local economy, Hampyeong County will hold prize events and special raffles for shoppers in the area, encouraging festival attendees to support local businesses. The festival will operate daily from 4 PM to 9 PM, and admission is free. Notably, the nighttime displays will remain in place until January 17, providing winter attractions for visitors to Hampyeong during the New Year period. Lee Nam-o, the mayor of Hampyeong County, stated, “This year’s Winter Light Festival is prepared to be a unique winter event by expanding the festival space to the town center and significantly enhancing the new light displays and performance content. We hope for much interest and many visits to make Hampyeong’s winter nights even more special.” Meanwhile, Hampyeong County aims to transform this year’s Winter Light Festival from a focus on nighttime scenery to a stay-oriented tourism festival that integrates performances, experiences, and local commerce, connecting the Expo Park and town center to invigorate the local economy during the winter season.* This article has been translated by AI.

Hyundai AutoEver Recognized as Top Honorary Company for Third Consecutive Year
Hyundai AutoEver Recognized as Top Honorary Company for Third Consecutive Year

Hyundai AutoEver has been recognized as a 'Top Honorary Company' for the third consecutive year in the evaluation of the Shared Growth Index.On November 17, Hyundai AutoEver announced that it was selected as a Top Honorary Company in the 2026 Shared Growth Index evaluation. This marks the first time since being included in the evaluation in 2014 that the company has achieved the top rating for three consecutive years.The Shared Growth Index is a metric that assesses the level of cooperative growth between large and small enterprises to promote mutual development. The Shared Growth Committee has been releasing evaluation results annually since 2011. The results combine the comprehensive evaluation of shared growth from the committee and the compliance evaluation from the Fair Trade Commission, categorizing companies into five grades: Excellent, Good, Average, Insufficient, and Very Insufficient.Hyundai AutoEver continues to support its partners in enhancing their business competitiveness and environmental, social, and governance (ESG) capabilities. The company is broadening its support scope across management and workforce operations by providing ESG consulting and assistance with recruitment and training.At the end of October, Hyundai AutoEver held the '2026 Hyundai AutoEver Partners Day.' This annual event is designed to share the direction of cooperative management with partner companies. This year, over 160 participants attended, including representatives from more than 60 partner companies that have signed shared growth agreements. Hyundai AutoEver awarded plaques and prizes to 15 partner companies that actively participated in shared growth activities.Lee Se-hee, Executive Director of Hyundai AutoEver's Management Support Division, stated, "Based on our three consecutive years of receiving the top rating and being named a Top Honorary Company for shared growth, we will continue to communicate closely with our partners and provide practical support for them."* This article has been translated by AI.

Bitcoin Holds Steady Around $65,000 Amid Extreme Fear
Bitcoin Holds Steady Around $65,000 Amid Extreme Fear

Bitcoin has recovered to the $65,000 range thanks to a rebound in buying pressure following a sharp decline, but it lacks clear upward momentum. Meanwhile, major altcoins are also showing weakness, and investor sentiment remains at an 'extreme fear' level. According to CoinMarketCap, as of 8 a.m. on November 17, Bitcoin was trading at $65,205, up 0.02% from 24 hours earlier. Most major altcoins experienced declines. Ethereum, the second-largest by market capitalization, fell 0.12% to $1,824. Ripple (XRP) dropped 1.06% to $0.9588, while Solana decreased by 0.74% to $71.78. Binance Coin (BNB) also saw a decline of 0.21%, trading at $593.80. Bitcoin had plummeted over the weekend due to uncertainties surrounding the U.S. Federal Reserve's monetary policy, large-scale liquidations, and regulatory concerns. It rebounded by 3.24% on November 16, regaining the $65,000 level, but the lack of additional buying pressure has stalled its upward trend. The risk-averse sentiment stemming from weakness in tech stocks is also weighing on the cryptocurrency market. Investor sentiment has shown little signs of recovery. CoinMarketCap's 'Fear and Greed Index' registered a score of 13, indicating 'extreme fear.' A score closer to 0 signifies extreme fear, while a score near 100 indicates extreme greed. Meanwhile, on the domestic cryptocurrency exchange Bithumb, Bitcoin was trading at 89,102,000 won, down 0.36% from the previous day. The Kimchi Premium, which reflects the price difference between domestic and international Bitcoin prices, was recorded at 2.193%. * This article has been translated by AI.

Korea Investment & Securities: Samsung Biologics Expected to Expand Earnings from PPGN Acquisition
Korea Investment & Securities: Samsung Biologics Expected to Expand Earnings from PPGN Acquisition

Korea Investment & Securities has projected that Samsung Biologics will see earnings growth due to its acquisition of PolyPeptide Group (PPGN) and the commercial production at its fifth plant. However, the firm noted that the existing plants have already reached high operational rates, leading to a slowdown in growth. They emphasized the need to resolve labor disputes and secure large orders for additional growth momentum. The investment recommendation remains a 'buy' with a target price of 1.95 million won.Analyst Wi Hae-joo forecasted in a report on November 13 that Samsung Biologics' revenue for 2027 will increase by 14% year-on-year to 6.3297 trillion won, with operating profit expected to rise by 11% to 2.6203 trillion won. The anticipated operating profit margin is 41%.Wi explained that since the first through fourth plants are expected to reach full operation in 2026, future profit growth will be driven by increased utilization of the fifth plant and operations at the U.S. facility.The U.S. plant is currently operating at about 50% capacity, expected to reach breakeven levels. The fifth plant is set to begin commercial production in the second half of next year, with an expected utilization rate of 16% and projected revenue of 289 billion won. Significant profit growth effects are anticipated starting in 2028.The potential for earnings expansion from the PPGN acquisition is viewed positively. Samsung Biologics plans to complete its capital increase and the PPGN acquisition process by the end of the year.The company also expects to benefit from the growth of the obesity treatment market. PPGN generated 57% of its revenue in 2025 from the production of peptides related to metabolic diseases. Among the 37 ongoing metabolic disease projects, seven are in Phase 3 clinical trials, indicating potential for additional orders upon commercialization.Wi projected that if PPGN's commercialization and late-stage clinical orders for metabolic diseases expand and operational efficiency improves, the standalone operating profit margin could rise to 20% by 2028.However, labor disputes and the possibility of order delays are identified as risk factors. In the contract manufacturing organization (CMO) business, supply chain stability and labor relations are critical evaluation factors for clients, meaning that resolving conflicts could impact new orders.Uncertainties surrounding U.S. regulations on China's WuXi AppTec also pose a variable. Wi noted that news of WuXi AppTec's removal from the list of Chinese military enterprises has had a somewhat negative impact on Samsung Biologics' stock price. The decision by the U.S. Office of Management and Budget (OMB) regarding the designation of concerned companies on December 18 could also influence investor sentiment.* This article has been translated by AI.

LS Electric Expands Vietnam Factory, Aims to Strengthen ASEAN Market Position
LS Electric Expands Vietnam Factory, Aims to Strengthen ASEAN Market Position

LS Electric has inaugurated its second production facility in Vietnam, aiming to strengthen its foothold in the ASEAN market.On November 16, LS Electric held a ceremony for the expansion of its production facility in the Yen Phong Industrial Park in Bac Ninh Province, attended by Chairman Koo Ja-kyun. Chairman Koo stated, "The second production facility in Bac Ninh will serve as a key strategic hub to enhance our leadership in the ASEAN market and drive global business expansion. We will secure overwhelming production capacity and an optimized local supply chain through bold and proactive investments to achieve global competitiveness."The newly completed second production building spans 7,611 square meters (approximately 2,302 pyeong) and consists of four floors. It will feature dedicated production lines for local strategic products, including Ring Main Units (RMUs), Battery Control Panels (BCPs) for Energy Storage Systems (ESS), and Air Circuit Breakers (ACBs).LS Electric's revenue from its Vietnamese subsidiary is expected to double from $83 million (approximately 110 billion won) in 2022 to $166 million (approximately 220 billion won) this year (2026).With this expansion, LS Electric aims to achieve $350 million (approximately 470 billion won) in revenue by 2030, continuing its goal of a "quantum leap" in revenue every four years.LS Electric was one of the first domestic power companies to enter Vietnam in the mid-1990s. It has maintained over 35% market share in the local low-voltage power equipment market since 2013. In October 2022, the company established a new factory in Bac Ninh to bolster its production capabilities.The ASEAN market has seen a surge in demand for power infrastructure due to increased investments in data centers by global companies, rapid expansion of renewable energy, and urbanization and industrialization.According to a global market research firm, the ASEAN power equipment market is projected to grow from approximately $32 billion (about 42.7 trillion won) in 2024 to around $46 billion (about 61.4 trillion won) by 2030, with an annual growth rate of over 6%.An LS Electric representative noted, "The second production facility in Bac Ninh has already secured the order volume needed for full operation next year, allowing us to commence production immediately. Given the explosive growth in local demand for power equipment, we will ensure timely supply and rigorous quality management to build market trust and establish ourselves as a reliable global power solutions partner centered in the ASEAN region."* This article has been translated by AI.